-
Mashup Score: 16Patient Navigation for Timely, Guideline-Adherent Adjuvant Therapy for Head and Neck Cancer: A National Landscape Analysis - 4 month(s) ago
Background: Aligned with the NCCN Clinical Practice Guidelines in Oncology for Head and Neck Cancers, in November 2021 the Commission on Cancer approved initiation of postoperative radiation therapy (PORT) within 6 weeks of surgery for head and neck cancer (HNC) as its first and only HNC quality metric. Unfortunately, >50% of patients do not commence PORT within 6 weeks, and delays disproportionately burden racial and ethnic minority groups. Although patient navigation (PN) is a potential strategy to improve the delivery of timely, equitable, guideline-adherent PORT, the national landscape of PN for this aspect of care is unknown. Materials and Methods: From September through November 2022, we conducted a survey of health care organizations that participate in the American Cancer Society National Navigation Roundtable to understand the scope of PN for delivering timely, guideline-adherent PORT for patients with HNC. Results: Of the 94 institutions that completed the survey, 89.4% (n=84
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Hypofractionated radiotherapy can be safe and effective for patients with locally advanced head and neck squamous cell carcinoma, a phase 3 trial suggests.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0LEAP-010 Study Discontinued for Patients with PD-L1-Expressing HNSCC - 8 month(s) ago
A coprimary end point in the phase 3 LEAP-010 study will not be met.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ASP-1929 Plus Pembrolizumab Generates Clinical Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - 9 month(s) ago
ASP-1929, an antibody-dye conjugate, plus pembrolizumab, induced a 29.4% overall response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ASP-1929 Plus Pembrolizumab Generates Clinical Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - 9 month(s) ago
ASP-1929, an antibody-dye conjugate, plus pembrolizumab, induced a 29.4% overall response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The phase 1b/2 ASP-1929-181 continues to investigate the photoimmunotherapy, ASP-1929, in combination with anti-EGFR therapy in patients with advanced head and neck cancer and other solid tumors.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Nivolumab and Chemoradiation HNSCC: DEPEND Trial - 10 month(s) ago
Ari Rosenberg, MD – Universiuty of Chicago The DEPEND trial investigated the use of neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). The study aimed to determine the feasibility of …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Adding nimorazole to radiotherapy does not improve outcomes in patients with locally advanced head and neck cancer who have tumor hypoxia, phase 3 data suggest.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Eftilagimod Alpha Added to Pembrolizumab Induces Hopeful Responses in Metastatic HNSCC - 11 month(s) ago
Eftilagimod alpha plus pembrolizumab showed an overall response rate of over 25% in patients with metastatic head and neck squamous cell carcinoma treated in the phase 2 TACTI-002 study.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 11 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Patient Navigation for Timely, Guideline-Adherent Adjuvant Therapy for Head and Neck Cancer: A National Landscape Analysis https://t.co/BaNe3j8zuP @JNCCN @oncologynursing @OncoAlert @helitropen #hnscc